Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.32, $0.09 better than the analyst estimate of $0.23. Revenue for the quarter came in at $163.8 million versus the consensus estimate of $155.22 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.